Author Archives: admin


Stem Cell Clinic > Articles by: admin

Akouos Announces Key Leadership Appointments

By Global News Feed

BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced the appointment of Sachiyo Minegishi as chief financial officer, effective today. In addition, the company announced that Jennifer Wellman has been promoted to chief operating officer, from her prior role as senior vice president of regulatory and quality.

Read the rest here:
Akouos Announces Key Leadership Appointments

Evaxion Biotech Launches New AI Powered Platform, RAVEN, to Enable Faster Response to Emerging Viral Pandemics

By Global News Feed

COPENHAGEN, Denmark, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Evaxion Biotech, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies and vaccines, announces today that it has received DKK 4.8 million (approx. $800,000) in funding from Innovation Fund Denmark for the development of its new RAVEN platform, an integral part of Evaxion’s Adaptive and Intelligent Vaccine for a Rapid Response against Corona Viruses (AICoV) program.

Continued here:
Evaxion Biotech Launches New AI Powered Platform, RAVEN, to Enable Faster Response to Emerging Viral Pandemics

Replimune to Participate at the Chardan Virtual 4th Annual Genetic Medicines Conference

By Global News Feed

WOBURN, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members of its senior management team will present in a fireside chat and host investor meetings at the Chardan Virtual 4th Annual Genetic Medicines Conference being held on October 6, 2020 at 4:45 p.m. ET.

Go here to read the rest:
Replimune to Participate at the Chardan Virtual 4th Annual Genetic Medicines Conference

AnPac Bio Announces Equity Investment from Keystone Capital Partners for up to $7 Million

By Global News Feed

SAN JOSE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today that the Company has entered into an agreement with Keystone Capital Partners (“Keystone”) for a preferred stock investment of US$7.0 Million. Additional details on the transaction are outlined in the accompanying Registration Statement filed on September 30, 2020 (File No. 333?249170).

Read the original here:
AnPac Bio Announces Equity Investment from Keystone Capital Partners for up to $7 Million

→←